Skip to main content
Erschienen in: The European Journal of Health Economics 6/2016

08.07.2015 | Original Paper

Predicting hospital costs for patients receiving renal replacement therapy to inform an economic evaluation

verfasst von: Bernadette Li, John Cairns, James Fotheringham, Rommel Ravanan, On behalf of the ATTOM Study Group

Erschienen in: The European Journal of Health Economics | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Objective

To develop a model to predict annual hospital costs for patients with established renal failure, taking into account the effect of patient and treatment characteristics of potential relevance for conducting an economic evaluation, such as age, comorbidities and time on treatment. The analysis focuses on factors leading to variations in inpatient and outpatient costs and excludes fixed costs associated with dialysis, transplant surgery and high cost drugs.

Methods

Annual costs of inpatient and outpatient hospital episodes for patients starting renal replacement therapy in England were obtained from a large retrospective dataset. Multiple imputation was performed to estimate missing costs due to administrative censoring. Two-part models were developed using logistic regression to first predict the probability of incurring any hospital costs before fitting generalised linear models to estimate the level of cost in patients with positive costs. Separate models were developed to predict inpatient and outpatient costs for each treatment modality.

Results

Data on hospital costs were available for 15,869 incident dialysis patients and 4511 incident transplant patients. The two-part models showed a decreasing trend in costs with increasing number of years on treatment, with the exception of dialysis outpatient costs. Age did not have a consistent effect on hospital costs; however, comorbidities such as diabetes and peripheral vascular disease were strong predictors of higher hospital costs in all four models.

Conclusion

Analysis of patient-level data can result in a deeper understanding of factors associated with variations in hospital costs and can improve the accuracy with which costs are estimated in the context of economic evaluations.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Tonelli, M., Wiebe, N., Knoll, G., Bello, A., Browne, S., Jadhav, D., Klarenbach, S., Gill, J.: Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am. J. Transplant. 11(10), 2093–2109 (2011)CrossRefPubMed Tonelli, M., Wiebe, N., Knoll, G., Bello, A., Browne, S., Jadhav, D., Klarenbach, S., Gill, J.: Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am. J. Transplant. 11(10), 2093–2109 (2011)CrossRefPubMed
3.
Zurück zum Zitat Rao, A., Steenkamp, R., Caskey, F.: UK Renal Registry 16th annual report. Chapter 5. Comorbidities and current smoking status amongst patients starting renal replacement therapy in England, Wales and Northern Ireland from 2011 to 2012. Nephron. Clin. Pract 125, 99–110 (2013)CrossRefPubMed Rao, A., Steenkamp, R., Caskey, F.: UK Renal Registry 16th annual report. Chapter 5. Comorbidities and current smoking status amongst patients starting renal replacement therapy in England, Wales and Northern Ireland from 2011 to 2012. Nephron. Clin. Pract 125, 99–110 (2013)CrossRefPubMed
4.
Zurück zum Zitat Metcalfe, W., Khan, I.H., Prescott, G.J., Simpson, K., Macleod, A.M.: Hospitalization in the first year of renal replacement therapy for end-stage renal disease. QJM 96(12), 899–909 (2003)CrossRefPubMed Metcalfe, W., Khan, I.H., Prescott, G.J., Simpson, K., Macleod, A.M.: Hospitalization in the first year of renal replacement therapy for end-stage renal disease. QJM 96(12), 899–909 (2003)CrossRefPubMed
6.
Zurück zum Zitat Fotheringham, J., Fogarty, D., Jacques, R., ElNahas, M., Campbell, M.: Chapter 13. The linkage of incident renal replacement therapy patients in England (2002–2006) to hospital episodes and national mortality data: improved demography and hospitalisation data in patients undergoing renal replacement therapy. Nephron. Clin. Pract 120(Suppl 1), c247–c260 (2012)CrossRefPubMed Fotheringham, J., Fogarty, D., Jacques, R., ElNahas, M., Campbell, M.: Chapter 13. The linkage of incident renal replacement therapy patients in England (2002–2006) to hospital episodes and national mortality data: improved demography and hospitalisation data in patients undergoing renal replacement therapy. Nephron. Clin. Pract 120(Suppl 1), c247–c260 (2012)CrossRefPubMed
9.
Zurück zum Zitat Mullahy, J.: Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J. Health. Econ. 17(3), 247–281 (1998)CrossRefPubMed Mullahy, J.: Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J. Health. Econ. 17(3), 247–281 (1998)CrossRefPubMed
10.
Zurück zum Zitat Dunn, G., Mirandola, M., Amaddeo, F., Tansella, M.: Describing, explaining or predicting mental health care costs: a guide to regression models. Methodological review. Br. J. Psychiatry 183, 398–404 (2003)CrossRefPubMed Dunn, G., Mirandola, M., Amaddeo, F., Tansella, M.: Describing, explaining or predicting mental health care costs: a guide to regression models. Methodological review. Br. J. Psychiatry 183, 398–404 (2003)CrossRefPubMed
11.
Zurück zum Zitat Buntin, M.B., Zaslavsky, A.M.: Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures. J. Health. Econ. 23(3), 525–542 (2004)CrossRefPubMed Buntin, M.B., Zaslavsky, A.M.: Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures. J. Health. Econ. 23(3), 525–542 (2004)CrossRefPubMed
12.
Zurück zum Zitat Barber, J., Thompson, S.: Multiple regression of cost data: use of generalised linear models. J. Health Serv. Res. Policy 9(4), 197–204 (2004)CrossRefPubMed Barber, J., Thompson, S.: Multiple regression of cost data: use of generalised linear models. J. Health Serv. Res. Policy 9(4), 197–204 (2004)CrossRefPubMed
13.
Zurück zum Zitat Hardin, J.W.H., J.M.: Generalized linear models and extensions, 2nd ed. Stata Press, Lakeway Drive, Texas (2007) Hardin, J.W.H., J.M.: Generalized linear models and extensions, 2nd ed. Stata Press, Lakeway Drive, Texas (2007)
14.
Zurück zum Zitat Kirkwood, B.R., Sterne, J.A.C.: Essential medical statistics, 2nd ed. Blackwell Publishing Oxford (2003) Kirkwood, B.R., Sterne, J.A.C.: Essential medical statistics, 2nd ed. Blackwell Publishing Oxford (2003)
15.
Zurück zum Zitat Haller, M., Gutjahr, G., Kramar, R., Harnoncourt, F., Oberbauer, R.: Cost-effectiveness analysis of renal replacement therapy in Austria. Nephrol. Dial. Transplant. 26(9), 2988–2995 (2011)CrossRefPubMed Haller, M., Gutjahr, G., Kramar, R., Harnoncourt, F., Oberbauer, R.: Cost-effectiveness analysis of renal replacement therapy in Austria. Nephrol. Dial. Transplant. 26(9), 2988–2995 (2011)CrossRefPubMed
16.
Zurück zum Zitat Howard, K., Salkeld, G., White, S., McDonald, S., Chadban, S., Craig, J.C., Cass, A.: The cost-effectiveness of increasing kidney transplantation and home-based dialysis. Nephrology 14(1), 123–132 (2009)CrossRefPubMed Howard, K., Salkeld, G., White, S., McDonald, S., Chadban, S., Craig, J.C., Cass, A.: The cost-effectiveness of increasing kidney transplantation and home-based dialysis. Nephrology 14(1), 123–132 (2009)CrossRefPubMed
17.
Zurück zum Zitat Jassal, S.V., Krahn, M.D., Naglie, G., Zaltzman, J.S., Roscoe, J.M., Cole, E.H., Redelmeier, D.A.: Kidney transplantation in the elderly: a decision analysis. J. Am. Soc. Nephrol. 14(1), 187–196 (2003)CrossRefPubMed Jassal, S.V., Krahn, M.D., Naglie, G., Zaltzman, J.S., Roscoe, J.M., Cole, E.H., Redelmeier, D.A.: Kidney transplantation in the elderly: a decision analysis. J. Am. Soc. Nephrol. 14(1), 187–196 (2003)CrossRefPubMed
18.
Zurück zum Zitat Kontodimopoulos, N., Niakas, D.: An estimate of lifelong costs and QALYs in renal replacement therapy based on patientsʼ life expectancy. Health Policy 86, 85–96 (2008)CrossRefPubMed Kontodimopoulos, N., Niakas, D.: An estimate of lifelong costs and QALYs in renal replacement therapy based on patientsʼ life expectancy. Health Policy 86, 85–96 (2008)CrossRefPubMed
19.
Zurück zum Zitat de Wit, G.A., Ramsteijn, P.G., de Charro, F.T.: Economic evaluation of end stage renal disease treatment. Health Policy 44, 215–232 (1998)CrossRefPubMed de Wit, G.A., Ramsteijn, P.G., de Charro, F.T.: Economic evaluation of end stage renal disease treatment. Health Policy 44, 215–232 (1998)CrossRefPubMed
20.
Zurück zum Zitat Wong, G., Howard, K., Chapman, J.R., Chadban, S., Cross, N., Tong, A., Webster, A.C., Craig, J.C.: Comparative survival and economic benefits of deceased donor kidney transplantation and dialysis in people with varying ages and co-morbidities. PLoS one 7(1) (2012) Wong, G., Howard, K., Chapman, J.R., Chadban, S., Cross, N., Tong, A., Webster, A.C., Craig, J.C.: Comparative survival and economic benefits of deceased donor kidney transplantation and dialysis in people with varying ages and co-morbidities. PLoS one 7(1) (2012)
21.
Zurück zum Zitat Briggs, A., Clark, T., Wolstenholme, J., Clarke, P.: Missing… presumed at random: cost-analysis of incomplete data. Health Econ. 12(5), 377–392 (2003)CrossRefPubMed Briggs, A., Clark, T., Wolstenholme, J., Clarke, P.: Missing… presumed at random: cost-analysis of incomplete data. Health Econ. 12(5), 377–392 (2003)CrossRefPubMed
22.
Zurück zum Zitat Sterne, J.A., White, I.R., Carlin, J.B., Spratt, M., Royston, P., Kenward, M.G., Wood, A.M., Carpenter, J.R.: Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 338, b2393 (2009)CrossRefPubMedPubMedCentral Sterne, J.A., White, I.R., Carlin, J.B., Spratt, M., Royston, P., Kenward, M.G., Wood, A.M., Carpenter, J.R.: Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 338, b2393 (2009)CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Bang, H.T., Tsiatis, A.A.: Estimating medical costs with censored data. Biometrika 87, 329–343 (2000)CrossRef Bang, H.T., Tsiatis, A.A.: Estimating medical costs with censored data. Biometrika 87, 329–343 (2000)CrossRef
24.
Zurück zum Zitat Carides, G.W., Heyse, J.F., Iglewicz, B.: A regression-based method for estimating mean treatment cost in the presence of right-censoring. Biostatistics 1(3), 299–313 (2000)CrossRefPubMed Carides, G.W., Heyse, J.F., Iglewicz, B.: A regression-based method for estimating mean treatment cost in the presence of right-censoring. Biostatistics 1(3), 299–313 (2000)CrossRefPubMed
25.
Zurück zum Zitat Lin, D.Y., Feuer, E.J., Etzioni, R., Wax, Y.: Estimating medical costs from incomplete follow-up data. Biometrics 53(2), 419–434 (1997)CrossRefPubMed Lin, D.Y., Feuer, E.J., Etzioni, R., Wax, Y.: Estimating medical costs from incomplete follow-up data. Biometrics 53(2), 419–434 (1997)CrossRefPubMed
26.
Zurück zum Zitat O’Hagan, A., Stevens, J.W.: On estimators of medical costs with censored data. J. Health Econ. 23(3), 615–625 (2004)CrossRefPubMed O’Hagan, A., Stevens, J.W.: On estimators of medical costs with censored data. J. Health Econ. 23(3), 615–625 (2004)CrossRefPubMed
27.
Zurück zum Zitat Young, T.A.: Estimating mean total costs in the presence of censoring: a comparative assessment of methods. Pharmacoeconomics 23(12), 1229–1242 (2005)CrossRefPubMed Young, T.A.: Estimating mean total costs in the presence of censoring: a comparative assessment of methods. Pharmacoeconomics 23(12), 1229–1242 (2005)CrossRefPubMed
Metadaten
Titel
Predicting hospital costs for patients receiving renal replacement therapy to inform an economic evaluation
verfasst von
Bernadette Li
John Cairns
James Fotheringham
Rommel Ravanan
On behalf of the ATTOM Study Group
Publikationsdatum
08.07.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
The European Journal of Health Economics / Ausgabe 6/2016
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-015-0705-x

Weitere Artikel der Ausgabe 6/2016

The European Journal of Health Economics 6/2016 Zur Ausgabe